OmniActive launches Curcuwin Ultra+, touting high bioavailability


Curcuwin Ultra+ offers low dose, highly bioavailable curcumin with low cost-in-use.

Photo © COLOA Studio

Photo © COLOA Studio

OmniActive Health Technologies (Morristown, NJ) launched Curcuwin Ultra+, a clinically studied, natural joint-health ingredient that is efficacious at a low dose with an excellent organoleptic profile. This allows for its use in challenging applications such as gummies and beverages, and a low cost-in-use.

“It’s no news that curcumin is still wildly popular with consumers, and as their demands evolved, we saw that there were multiple gaps arising in the market,” said Sayantan Bhattacharya, senior director, category manager who oversees OmniActive’s branded curcumin products, in a press release. “Curcuwin Ultra+ addresses several of these challenges in a single, convenient ingredient.” 

Curcuwin Ultra+ uses a specialized process that incorporates bioenhancers to better protect and deliver more curcuminoids than standard curcumin. According to Omniactive, a clinical study found that the ingredient was 144x more bioavailable compared to standard curcumin. Because it is made using Ultrasol, the same foundational technology as its predecessor, Curcumin Ultra+ also comes with the same clinically supported heart health and sports nutrition benefits as the original Curcuwin.

“This product aims at disrupting how brands formulate with curcumin in an era where consumers are constantly looking at convenient solutions that can deliver more for less,” said Isabel Lucas, director of product launch and marketing excellence, for OmniActive. “We believe people will be highly interested in Curcuwin Ultra+ because of its clinically demonstrated bioavailability and that it addresses consumer needs in the joint health, sports nutrition and active wellness markets.”

Related Videos
woman working on laptop computer by window
© 2024 MJH Life Sciences

All rights reserved.